X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
open-label (2256) 2256
index medicus (2013) 2013
humans (1858) 1858
double-blind (1007) 1007
male (736) 736
pharmacology & pharmacy (726) 726
female (714) 714
treatment outcome (581) 581
efficacy (512) 512
middle aged (506) 506
care and treatment (482) 482
adult (477) 477
safety (476) 476
oncology (458) 458
clinical trials (440) 440
medicine & public health (437) 437
drug therapy (431) 431
aged (402) 402
clinical neurology (384) 384
patients (331) 331
placebo-controlled trial (306) 306
analysis (301) 301
research (296) 296
chemotherapy (284) 284
psychiatry (274) 274
cancer (249) 249
internal medicine (231) 231
review (225) 225
health aspects (221) 221
therapy (216) 216
multicenter (214) 214
animals (213) 213
randomized controlled trials as topic (211) 211
quality-of-life (210) 210
neurosciences (208) 208
pharmacotherapy (207) 207
studies (204) 204
adolescent (203) 203
dosage and administration (190) 190
quality of life (190) 190
open-label extension (185) 185
diabetes (182) 182
mutation (178) 178
endocrinology & metabolism (177) 177
medical research (177) 177
child (174) 174
diabetes mellitus, type 2 - drug therapy (172) 172
clinical trials as topic (171) 171
metastasis (170) 170
neurology (170) 170
double-blind method (162) 162
pharmacology/toxicology (161) 161
type 2 diabetes (161) 161
medicine, general & internal (155) 155
risk factors (154) 154
trial (153) 153
usage (152) 152
aged, 80 and over (149) 149
drug therapy, combination (148) 148
randomized controlled-trial (148) 148
children (146) 146
glycemic control (144) 144
pharmacokinetics (144) 144
1st-line treatment (143) 143
phase-iii (141) 141
cancer therapies (137) 137
management (134) 134
dose-response relationship, drug (133) 133
young adult (133) 133
tolerability (130) 130
pharmacology (128) 128
rheumatology (127) 127
time factors (127) 127
tumors (124) 124
medicine, experimental (123) 123
medicine, research & experimental (123) 123
drug dosages (119) 119
lung cancer (119) 119
drug administration schedule (117) 117
insulin (117) 117
pediatrics (116) 116
complications and side effects (113) 113
antineoplastic agents - therapeutic use (111) 111
hypoglycemic agents - therapeutic use (111) 111
severity of illness index (110) 110
toxicology (110) 110
antipsychotic agents - therapeutic use (109) 109
survival (109) 109
hematology (107) 107
immunotherapy (107) 107
patient outcomes (107) 107
dermatology (106) 106
drugs (104) 104
retrospective studies (103) 103
psoriasis (102) 102
development and progression (101) 101
immunology (101) 101
open-label trial (101) 101
abridged index medicus (99) 99
surgery (99) 99
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2642) 2642
German (9) 9
French (5) 5
Spanish (3) 3
Japanese (2) 2
Chinese (1) 1
Georgian (1) 1
Hungarian (1) 1
Korean (1) 1
Russian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2019, Volume 321, Issue 16, pp. 1610 - 1620
IMPORTANCE: The quality of reporting of randomized clinical trials is suboptimal. In an era in which the need for greater research transparency is paramount,... 
MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | MULTIPLICITY | THERAPY | EFFICACY | REDUCTION | CLINICAL-TRIALS | OPEN-LABEL | ADJUSTMENT | Clinical trials | Practice guidelines (Medicine) | Analysis | Disclosure of information | Medical research | Randomization | Statistical analysis | Judgments | Reliability analysis | Reporting
Journal Article
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 12, pp. 1288 - 1296
Journal Article
Journal Article
Clinical therapeutics, ISSN 0149-2918, 2007, Volume 29, Issue 9, pp. 2068 - 2079
... in randomized controlled trials in the treatment of CNP in patients with MS. Objective: The purpose of this extension was to establish long-term tolerability and effectiveness profiles for THC/CBD (Sativex... 
Internal Medicine | Medical Education | open-label extension trial | central pain | neuropathic pain | cannabinoid | multiple sclerosis | Sativex | Ag-tetrahydrocannabinol/cannabidiol
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 09/2019, Volume 71, Issue 9, pp. 1450 - 1459
... phase III and 2 long‐term extension studies over 7 years. MACE (myocardial infarction, stroke, cardiovascular death... 
Blood Sedimentation | Myocardial Infarction - epidemiology | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Arthritis, Rheumatoid - complications | Incidence | Clinical Trials, Phase III as Topic | Arthritis, Rheumatoid - drug therapy | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Stroke - epidemiology | Pyrroles - therapeutic use | Myocardial Infarction - etiology | Cardiovascular Diseases - etiology | Risk Factors | Proportional Hazards Models | Treatment Outcome | Stroke - etiology | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Cholesterol, HDL - blood | Aged | BACKGROUND METHOTREXATE | JAK INHIBITOR | PLACEBO | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | LIPID-LEVELS | DISEASE | OPEN-LABEL | RHEUMATOLOGY | JAPANESE PATIENTS | CP-690,550 | Myocardial infarction | Lipoproteins (low density) | Glucocorticoids | Erythrocytes | Arthritis | Density | Risk factors | Confidence intervals | Regression models | Red blood cells | Erythrocyte sedimentation rate | Lipoproteins (high density) | Hypertension | Cerebral infarction | Sedimentation rates | Stroke | Statistical analysis | Health risks | Regression analysis | Risk analysis | Sedimentation | Patients | Cholesterol | Rheumatoid arthritis | Cardiovascular diseases | Health risk assessment
Journal Article
Journal Article
Schizophrenia Research, ISSN 0920-9964, 2017, Volume 192, pp. 205 - 210
...) in patients with schizophrenia. Methods Patients who completed the QUALIFY study ( NCT01795547 ) in the AOM 400 arm were eligible for 6 additional once-monthly injections of AOM 400 during an open-label, 24-week extension... 
Psychiatry | Schizophrenia | Aripiprazole once-monthly | Maintenance treatment | Quality of life | PSYCHIATRY WFSBP GUIDELINES | MULTICENTER | PSYCHIATRY | OPEN-LABEL | BIOLOGICAL TREATMENT | ANTIPSYCHOTICS | DOUBLE-BLIND | LIFE SCALE | PART 2 | WORLD FEDERATION | Aripiprazole | Analysis
Journal Article
Multiple sclerosis, ISSN 1477-0970, 2017, Volume 23, Issue 14, pp. 1909 - 1917
Journal Article